PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
3986.96%
Growth of 3986.96% while TRAW shows flat revenue. Bruce Berkowitz would examine growth quality advantage.
No Data
No Data available this quarter, please select a different quarter.
804.39%
Gross profit growth exceeding 1.5x TRAW's 1.92%. David Dodd would verify competitive advantages.
117.23%
Margin expansion exceeding 1.5x TRAW's 1.92%. David Dodd would verify competitive advantages.
-19.33%
R&D reduction while TRAW shows 14.82% growth. Joel Greenblatt would examine competitive risk.
-34.65%
G&A reduction while TRAW shows 0.00% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-24.37%
Operating expenses reduction while TRAW shows 9.70% growth. Joel Greenblatt would examine advantage.
-24.37%
Total costs reduction while TRAW shows 9.66% growth. Joel Greenblatt would examine advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
36.46%
EBITDA growth while TRAW declines. John Neff would investigate advantages.
98.45%
EBITDA margin growth while TRAW declines. John Neff would investigate advantages.
35.83%
Operating income growth while TRAW declines. John Neff would investigate advantages.
98.43%
Operating margin growth while TRAW declines. John Neff would investigate advantages.
-7.89%
Other expenses reduction while TRAW shows 1100.00% growth. Joel Greenblatt would examine advantage.
35.97%
Pre-tax income growth while TRAW declines. John Neff would investigate advantages.
98.43%
Pre-tax margin growth while TRAW declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
36.40%
Net income growth while TRAW declines. John Neff would investigate advantages.
98.44%
Net margin growth while TRAW declines. John Neff would investigate advantages.
37.84%
EPS growth while TRAW declines. John Neff would investigate advantages.
37.84%
Diluted EPS growth while TRAW declines. John Neff would investigate advantages.
2.81%
Share count reduction below 50% of TRAW's 0.04%. Michael Burry would check for concerns.
2.81%
Diluted share reduction below 50% of TRAW's 0.04%. Michael Burry would check for concerns.